Movement Alert｜CRISPR Therapeutics AG Intraday Decline 5.01%, valuation debate and recent earnings miss weigh on shares

Market Focus11-12 23:25

On November 12, CRISPR Therapeutics AG fell 5.01% in Regular Trading, trading at $43.44 per share, with turnover of $18.8672 million.

The most recent market update tied the weakness to renewed valuation debate after recent clinical disclosures, alongside pressure from the company’s latest quarterly results. CRISPR Therapeutics AG previously reported September-quarter EPS of $1.15 loss, wider than the $0.98 loss expected by analysts, although revenue of $12.669 million exceeded estimates.

Recent pipeline news was constructive but did not prevent the selloff. On November 9, the company presented Phase 1b data for CTX310 showing mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides after a single-course treatment. Earlier, autoimmune data for zugo-cel also showed encouraging early responses. Even so, the latest market interpretation emphasized continuing losses and uncertainty around commercialization timing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment